3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
3
Melanoma
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Locally Advanced Thyroid Gland Carcinoma
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
Cisplatin
19
Docetaxel
17
Cetuximab
12
Carboplatin
12
Radiotherapy
11
Magnetic Resonance Spectroscopy
10
Biopsy
10
pembrolizumab
9
Paclitaxel
9
Radiotherapy, Intensity-Modulated
8
Immunohistochemistry
8
Erlotinib Hydrochloride
8
Trastuzumab
7
Gemcitabine
7
Chemotherapy, Adjuvant
7
Specimen Handling
6
Radiotherapy, Conformal
5
Radiosurgery
5
Gene Expression Profiling
5
Fluorodeoxyglucose F18
5
Capecitabine
5
Vorinostat
4
Taxes
4
Sorafenib
4
Polymerase Chain Reaction
4
Nivolumab
4
Bevacizumab
4
trastuzumab deruxtecan
3
sargramostim
3
bicalutamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
larotrectinib
×
Head & Neck
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA